This 2022 extension of the STEP 1 trial assessed the effects of discontinuing semaglutide 2.4 mg weekly in adults with obesity. After 68 weeks of treatment, participants had lost an average of 17.3% of their body weight. One year post-withdrawal, they regained approximately two-thirds of this weight loss, resulting in
This 2023 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of once-weekly semaglutide (2.4 mg) in 201 adolescents aged 12 to
This 2022 pharmacovigilance study analyzed FDA Adverse Event Reporting System (FAERS) data to assess the association between GLP-1 receptor agonists (GLP-1 RAs) and acute cholecystitis. The analysis revealed a notable number of reports linking GLP-1 RAs, such as liraglutide and semaglutide, to cases of acute cholecystitis. The proposed mechanism involves
The STEP 8 trial was a 68-week, randomized, double-blind, double-dummy, phase 3 clinical study comparing once-weekly subcutaneous semaglutide 2.4 mg to once-daily subcutaneous liraglutide 3.0 mg in 338 adults with overweight or obesity without diabetes. Participants received lifestyle interventions alongside medication. Semaglutide led to a greater mean weight loss (−15.8%)
This meta-analysis demonstrated that subcutaneous semaglutide significantly reduced body weight by up to 14.9%, improved glycemic control with an average HbA1c reduction of 1.7%, and had a manageable safety profile dominated by gastrointestinal side effects. It involved over 1,961 participants, predominantly adults with obesity, and highlighted semaglutide’s potential to enhance
